ParcelBio Raises $13M Seed to Advance Durable mRNA Platform for Autoimmune and Oncology Therapies

Biotech startups still walk into the room talking like they already cured mortality. Whiteboards full of arrows. Everybody promising the future of medicine while quietly praying the centrifuge stops making that noise in the corner. ParcelBio came out different. No chest pounding. No sci-fi cosplay wrapped in investor jargon. Just a San Francisco company stepping out of stealth with $13M in seed financing and a dangerous idea: what if mRNA medicines didn’t disappear before the real work starts?

That funding came from Breyer Capital, with General Catalyst, Y Combinator, Metaplanet, SurgePoint Capital, and ZAKA VC joining the round. David Weinberg, Ph.D., Co-founder and CEO, and Chris Carlson, Ph.D., Co-founder and CSO, are building ParcelBio around APEXm, short for Amplified and Prolonged EXpression mRNA. The goal: engineer mRNA medicines capable of stronger and longer-lasting protein expression without creating a manufacturing problem nobody can scale.

One of the biggest frustrations in RNA therapeutics is durability. Conventional mRNA can generate impressive expression, then fade before sustained therapeutic impact is achieved. Fine for some applications. Not ideal when targeting autoimmune disease, oncology, or therapeutic proteins where persistence changes outcomes entirely. Biology does not care how polished the investor deck looks. Cells either cooperate or they don’t.

ParcelBio’s answer is APEXm. Instead of forcing biology into submission, the platform recruits the cell’s native RNA-stabilizing machinery while maintaining a simple linear mRNA architecture. In plain English, the company is trying to make mRNA medicines more potent and durable without overengineering the system into oblivion. Scientific elegance means nothing if manufacturing, dosing windows, regulatory timelines, and economics collapse under pressure.

The pipeline shows they understand where this technology matters most. In autoimmune disease, ParcelBio is pursuing in vivo CAR-T approaches targeting pathogenic B cells with the goal of deeper immune reset and durable drug-free remission. In oncology, the platform is being developed for programmable control over potency, duration, and redosing.

The advisory bench adds credibility fast. Rachel Green, Ph.D., Stuart Milstein, Ph.D., Robbie Majzner, M.D., Megan Yung, J.D. Ph.D., and Bret Bostwick, M.D. bring expertise spanning RNA biology, CAR-T therapy, translational medicine, and biotech commercialization.

The mRNA sector got loud after 2020. Every company suddenly sounded revolutionary. ParcelBio feels more disciplined than theatrical. Less obsession with speed alone. More focus on durability, controllability, and therapeutic thresholds existing mRNA platforms still struggle to reach. In biotech, the difference between a breakthrough and a science project usually comes down to whether the medicine lasts long enough to matter.